Data on the efficacy of bilateral prophylactic mastectomy for breast cancer risk reduction in women with BRCA1 and BRCA2 (BRCA1/2) mutations are limited, despite the clinical use of this risk-management strategy. Thus, we estimated the degree of breast cancer risk reduction after surgery in women who carry these mutations.
INTRODUCTION
Women with germline BRCA1 or BRCA2 (BRCA1/2) mutations have a markedly increased risk of breast and ovarian cancer compared with the general population [1] [2] [3] . These women sometimes elect bilateral prophylactic mastectomy to reduce their risk of breast cancer. However, data on breast cancer risk reduction after bilateral prophylactic mastectomy in this high-risk group are limited. Hartmann et al [4] evaluated the efficacy of bilateral prophylactic mastectomy in a retrospective cohort analysis of 639 moderate-and high-risk women who had bilateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. Data from this study suggest that bilateral prophylactic mastectomy is associated with a 90% reduction in breast cancer incidence and mortality in women at high risk of breast cancer. However, BRCA1/2 mutation status was unavailable for the initial analysis, and only 18 women in this series were later reported to be BRCA1/2 mutation carriers [5] . Postbilateral prophylactic mastectomy breast cancer risk reduction in this small group of mutation carriers was estimated at 89% to 100%, but the 95% CIs were large.
In the only other study of BRCA1/2 mutation carriers to date, Meijers-Heijboer et al [6] reported no postbilateral prophylactic mastectomy breast cancers in 76 BRCA1/2 mutation carriers after 2.9 years of follow-up, compared with eight breast cancers in 63 mutation carriers who did not undergo bilateral prophylactic mastectomy (P ϭ .003). These data suggest that bilateral prophylactic mastectomy confers substantial breast cancer risk reduction in BRCA1/2 mutation carriers, but accurate estimates of the magnitude of this risk reduction could not be determined from this study. We measured the incidence of breast cancer in 483 BRCA1/2 mutation carriers (105 surgical subjects and 378 matched controls) using a case-control sample drawn from a historical cohort using an incidence density sampling design.
PATIENTS AND METHODS

Study Participants
Women with germline, disease-associated BRCA1/2 mutations were identified from 11 North American and European institutions (Creighton University, The Dana-Farber Cancer Institute, The Fox Chase Cancer Center, Georgetown University, University of Chicago, University of Pennsylvania, University of Utah, the Netherlands Cancer Institute, St. Mary's Hospital, Women's College Hospital, and Yale University). The BRCA1/2 mutation status of all subjects was confirmed by direct mutation testing with full informed consent under protocols approved by the human subjects review boards at each institution. Women with BRCA1/2 variants of unknown functional significance were excluded. Two groups of women were studied. First, we studied women who underwent bilateral prophylactic mastectomy. Second, we studied controls without either bilateral prophylactic mastectomy or breast cancer at the time of the matched subject's surgery. One or more controls were selected per surgical subject if they could be matched on type of mutation, treatment center, and year of birth within 5 years. Study participants were excluded if they had prior or concurrent breast cancer at time of surgery. Women who underwent prophylactic mastectomy had one of the following four surgical procedures (if known) as noted in Table 1 : total (simple) mastectomy (ie, removal of both breasts and overlying skin without axillary dissections); subcutaneous mastectomy (ie, removal of both breasts with preservation of overlying skin and nipple-areolar complexes); modified radical mastectomy (ie, removal of both breasts with overlying skin and axillary contents); and radical mastectomy (ie, removal of both breasts with overlying skin, pectoralis muscles, and axillary contents). All procedures were confirmed by medical record and/or pathology reports as prophylactic, not therapeutic.
As summarized in Table 1 , four analyses were performed to fully explore the breast cancer risk reduction associated with bilateral prophylactic mastectomy and to consider the effects of oophorectomy on this risk reduction. Cases and controls were observed prospectively from the time of their center ascertainment and surgery (cases only), with analyses performed for both follow-up periods. In an attempt to eliminate selection bias potentially introduced by women with a documented previous breast cancer diagnosis, a second set of analyses was preformed using only cases and controls that had not had bilateral prophylactic mastectomy at the time of center ascertainment. Therefore, for analyses 3 and 4, controls were also matched on year of ascertainment. In addition, analyses 1 and 3 were adjusted for duration of endogenous ovarian hormone exposure, including age at bilateral prophylactic oophorectomy. The total sample from which individuals were drawn included 483 women, including 105 who underwent bilateral prophylactic mastectomy and 378 who did not. Analysis 1 was the largest sample, including 480 individuals (99.4%) of the total sample size. Three eligible bilateral prophylactic mastectomy subjects were not included in Analysis 1 because matching of 102 bilateral prophylactic mastectomy subjects exhausted the availability of all 378 controls. Because not all bilateral prophylactic mastectomy subjects were eligible for analyses 2, 3, and 4, controls became available, and these three cases were included in these analyses. For each analysis, controls were rematched to all eligible bilateral prophylactic mastectomy subjects, respecting each specific sample set criteria (Table 1 ), to achieve the largest possible sample sizes.
Analysis 1 (follow-up from center ascertainment, all cases and controls). Four hundred eighty study participants were included in this analysis regardless of their bilateral prophylactic mastectomy, bilateral prophylactic oophorectomy, or breast cancer status at the time of center ascertainment. Cases were eligible if they had a disease-associated BRCA1/2 mutation, had undergone bilateral prophylactic mastectomy, and had not been diagnosed with breast or ovarian cancer before bilateral prophylactic mastectomy. Controls were eligible if they were alive and cancer-free with both breasts intact at the time of the matched subject's bilateral prophylactic mastectomy. Survival analyses were adjusted to account for duration of endogenous ovarian hormone exposure as measured by the time from age at menarche to age at bilateral prophylactic oophorectomy or menopause, whichever was sooner. Thus, this is a mixed prospective and retrospective analysis of bilateral prophylactic mastectomy effect adjusted for duration of endogenous ovarian hormone exposure that included 102 bilateral prophylactic mastectomy subjects and 378 controls.
Analysis 2 (follow-up from center ascertainment, no prior or concurrent bilateral prophylactic oophorectomy).
This analysis was performed on the subset of women from the total sample who had undergone bilateral prophylactic mastectomy but had not undergone bilateral prophylactic oophorectomy before this procedure. Controls were eligible if they had not undergone bilateral prophylactic oophorectomy and were alive and cancer-free with both breasts intact at the time of the matched subject's bilateral prophylactic mastectomy. Thus, this is an analysis of bilateral prophylactic mastectomy effect in BRCA1/2 mutation carriers with no prior or concurrent bilateral prophylactic oophorectomy that included 59 bilateral prophylactic mastectomy subjects and 305 controls.
Analysis 3 (follow-up from bilateral prophylactic mastectomy after center ascertainment). This analysis was performed on the subset of women who had not had bilateral prophylactic mastectomy at the time of their center ascertainment. Controls were excluded if they had a diagnosis of breast or ovarian cancer at or before the time of the matched surgical subject's bilateral prophylactic mastectomy. As in analysis 1, surgical subjects and matched controls were included regardless of their history of bilateral prophylactic oophorectomy, and survival analyses were adjusted to account for the duration of exposure to endogenous ovarian hormones. Thus, this is a prospective analysis of bilateral prophylactic mastectomy effect adjusted for duration of endogenous ovarian hormone exposure that included 57 bilateral prophylactic mastectomy subjects and 107 controls.
Analysis 4 (follow-up from bilateral prophylactic mastectomy after center ascertainment, no prior or concurrent bilateral prophylactic oophorectomy). This analysis was performed on the subset of women who had not had bilateral prophylactic mastectomy at the time of their center ascertainment and had not undergone bilateral prophylactic oophorectomy at or before bilateral prophylactic mastectomy. Controls were ineligible if they had a diagnosis of breast or ovarian cancer or had undergone bilateral prophylactic oophorectomy at or before the time of the matched surgical subject's bilateral prophylactic mastectomy. Thus, this is a prospective analysis of bilateral prophylactic mastectomy effect in the absence of bilateral prophylactic oophorectomy that included 28 bilateral prophylactic mastectomy subjects and 69 controls.
Data Collection and Statistical Analysis
Entry and follow-up at each center were undertaken without regard to surgical status. Vital status and cancer diagnoses were obtained using telephone interviews and/or self-administered questionnaires and verified with medical records, pathology reports, and/or cancer registries. Reproductive and smoking history, exogenous hormone use, and alcohol consumption were obtained by questionnaire. For women who had died since center ascertainment, medical records were used to verify information provided by family members.
Cox proportional hazards models were used to estimate differences in cancer incidence by bilateral prophylactic mastectomy status using STATA (release 7; STATA Corp, College Station, TX). A robust variance-covariance estimation method [7] was used to correct for nonindependence of observations among subjects from the same family. Surgical subjects and controls were observed from the date of the surgical subject's bilateral prophylactic mastectomy until a diagnosis of breast cancer or a censoring event. Subjects were censored at the date they developed ovarian cancer, underwent bilateral prophylactic oophorectomy (analyses 2 and 4 only), or died, or at the date of last contact. Diagnosis of invasive breast cancer or ductal carcinoma-in-situ was considered the primary event of interest.
RESULTS
Characteristics of the entire sample are listed in Table 2 . Characteristics of the bilateral prophylactic mastectomy subjects and matched controls by analysis are listed in Tables 3 and 4. Mean age at time of surgery for the whole sample was 38.1 years. Follow-up of controls began at a mean age of 36.3 years. Postsurgery follow-up duration was 5.5 years in cases and 6.7 years in controls. Of the 105 mutation carriers with bilateral prophylactic mastectomy (cases) in the total cohort, two (1.9%) were diagnosed with breast cancer after bilateral prophylactic mastectomy (both subcutaneous) compared with 184 (48.7%) of 378 controls. Two additional controls developed breast cancer but were censored because of a prior diagnosis of ovarian cancer. Pathology records of the two women with postbilateral prophylactic mastectomy breast cancer indicated no detectable evidence of breast cancer at the time of prophylactic surgery. These breast cancers occurred 2.3 and 9.2 years after bilateral prophylactic mastectomy. Figure 1 presents a Kaplan-Meier analysis of breast cancer events by postsurgery follow-up time in cases compared with controls. The first postsurgery breast cancer case had an R2520X mutation in BRCA2 and underwent bilateral prophylactic mastectomy at age 26 years. Twenty-seven months later, at age 28 years, a palpable axillary mass was found to be metastatic adenocarcinoma in an axillary lymph node consistent with a breast primary. No primary or metastatic tumor was identified elsewhere by bone scan, abdominal computed tomography scan, or chest x-ray. The second postsurgery breast cancer case had a 188del11 mutation in BRCA1 and underwent bilateral prophylactic mastectomy at age 32 years. Nine years later, she was diagnosed with ductal carcinoma-in-situ and an adjacent stage II infiltrating ductal carcinoma in substantial residual right breast tissue. This subject was later diagnosed with poorly differentiated grade 3 ovarian cancer of mixed serous and mucinous histology at age 47 years.
Compared with controls, the occurrence of postbilateral prophylactic mastectomy breast cancer in cases corresponds to a hazard ratio of 0.05 to 0.09 (Table 5, analyses 1 and 2), confirming a substantial and statistically significant reduction in breast cancer risk after bilateral prophylactic mastectomy in BRCA1/2 mutation carriers. In the most rigorous analysis, no women with bilateral prophylactic mastectomy in the purely prospective groups (analyses 3 and 4) were diagnosed with breast cancer after 3.0 and 2.9 mean years of follow-up, respectively, compared with 24 of 107 controls in analysis 3 (P Ͻ .001) and 19 of 69 controls in analysis 4 (P Ͻ .001; Table 4 ). The absence of postbilateral prophylactic mastectomy breast cancers precludes formal estimation of the magnitude of risk reduction associated with bilateral prophylactic mastectomy in the purely prospective analyses.
DISCUSSION
These data indicate that bilateral prophylactic mastectomy reduces the risk of breast cancer by approximately 90% in BRCA1/2 mutation carriers. Assuming a breast cancer risk to age 70 years of 73% in the clinic-based populations studied here [8] , this 90% risk reduction translates into a breast cancer risk in BRCA1/2 mutation carriers of 7% to age 70 years. Although formal analyses have yet to be performed because of insufficient follow-up time and number of deaths in our sample, it can be inferred that this risk reduction will be associated with a marked reduction in breast cancer mortality. Our estimates of risk reduction are consistent with previous reports of the efficacy of bilateral prophylactic mastectomy in women with unknown BRCA1/2 mutation status. In the retrospective cohort analysis by Hartmann et al [4] , bilateral prophylactic mastectomy was associated with a 90% reduction in expected breast cancer incidence and mortality in both the moderate-and high-risk groups. As in the current study, all postbilateral prophylactic mastectomy breast cancers occurred after subcutaneous mastectomy. In a study of 139 BRCA1/2 mutation carriers, Meijers-Heijboer et al [6] compared the observed versus expected proportion of breast cancer in 76 mutation carriers who underwent bilateral prophylactic mastectomy and 63 mutation carriers who did not have the procedure. No cases of breast cancer were diagnosed after bilateral prophylactic mastectomy compared with eight diagnosed breast cancers after 3 years of follow-up in women who did not have the surgery. Together with the current study, these analyses conclusively demonstrate significant and substantial breast cancer risk reduction after bilateral prophylactic mastectomy in BRCA1/2 mutation carriers.
Although a prospective, randomized clinical trial would be the methodologically ideal approach to evaluate the efficacy of bilateral prophylactic mastectomy, such a trial is not feasible because few women would agree to be randomly assigned to bilateral prophylactic mastectomy versus observation. Similarly, a purely prospective study design would limit chances that selection or survival biases would influence the estimate of risk reduction associated with bilateral prophylactic mastectomy. However, the number of mutation carriers and length of time required for such a study would preclude us from providing women with an assessment of the efficacy of bilateral prophylactic mastectomy for the foreseeable future. In this study, we analyzed both our total cohort and the purely prospective subset of women who had bilateral prophylactic mastectomy after center ascertainment. Potential sources of bias in our study design include confounding by indication and competing events [9] . Confounding by indication could affect the analyses if the reasons for undergoing bilateral prophylactic mastectomy are related to risk of breast cancer. Under this scenario, controls at greater risk of developing breast cancer would have to be less likely to undergo surgery than women with less risk. Although unlikely, this effect would lead to an underestimation in risk reduction. Because we estimated risk reduction at close to 95%, the possible underestimation of risk reduction is minimal at . Additionally, the sample used for the current study is representative of the population of women who attend high-risk clinics for genetic testing and discussion of risk-management options. Thus, we are able to estimate breast cancer risk reduction using a matched study design that corrects for many of the limitations of a mixed prospective-retrospective cohort design while circumventing the time and study size considerations of a purely prospective study. In this study, only two women were diagnosed with breast cancer after bilateral prophylactic mastectomy; thus, we cannot make strong inferences about optimal type and timing of surgery or about risk factors that may influence postbilateral prophylactic mastectomy breast cancers. However, both failures occurred in women with subcutaneous mastectomies. Unfortunately, one of the failures (and the subsequent death of the patient) likely would have occurred regardless of the type of procedure because it most probably represented microscopic primary breast cancer metastatic to axillary lymph nodes at the time of surgery. However, the other failure may have been preventable because this woman developed a noninvasive breast cancer that progressed to invasive disease in residual breast epithelium. In our cohort, about one third of women in whom surgical procedure could be unequivocally determined underwent subcutaneous mastectomy. Subcutaneous bilateral prophylactic mastectomy leaves substantial residual breast tissue intact, including the nipple-areolar complex and, therefore, is not optimal for a prophylactic procedure. Total mastectomy requires more extensive reconstruction and may result in an inferior cosmetic result, but it removes substantially more breast tissue. However, the recently developed skin-sparing mastectomy with immediate reconstruction combines adequate tissue removal with excellent cosmetic outcome [12] . Thus, this procedure is an excellent choice for bilateral prophylactic mastectomy where a qualified general or plastic surgical team is available. Regardless of the selected procedure, care should be taken to remove as much breast tissue as possible to maximize risk reduction.
There are surgical and anesthetic risks that should be considered when offering prophylactic surgery to a healthy individual [13] . In a recent series of 112 high-risk women (79 with a BRCA1/2 mutation) who underwent prophylactic mastectomy (103 with immediate reconstruction), 21% had complications, including hematoma, infection, contracture, or implant rupture [14] . Use of autologous tissue, such as with transverse rectus abdominis musculocutaneous (TRAM) or latissimus dorsi reconstruction, may eliminate the need for silicone implants, but complication rates may be even higher. In one series of 147 breast cancer patients with TRAM reconstruction after mastectomy, follow-up operations were necessary in 71% of patients, including intervention for complications such as abdominal hernia, full or partial TRAM ischemic loss, and fat necrosis [15] .
Our long-term goal is to provide effective nonsurgical breast cancer prevention to all high-risk women. Numerous epidemiologic studies suggest that breast cancer risk in BRCA1/2 mutation carriers is influenced by estrogen exposure in a manner analogous to that of the general population [16] . This effect is also seen in the 50% breast cancer risk reduction we reported in association with bilateral prophylactic oophorectomy [7, 17] . These findings suggest that breast cancer risk in BRCA1/2 mutation carriers is likely to be reduced by chemopreventive agents such as tamoxifen. Unfortunately, the Breast Cancer Prevention Trial data do not provide adequate information on chemoprevention in women with BRCA1 mutations. Because only eight BRCA1 mutation carriers were diagnosed with breast cancer in the Breast Cancer Prevention Trial [18] (five on tamoxifen and three on placebo) and the results were not statistically significant from that small sample (odds ratio, 1.67; 95% CI, 0.41 to 8.00), conclusions cannot be drawn regarding tamoxifen efficacy in this setting. Although limited inferences can be drawn from retrospective studies, many studies suggest that reducing estrogen effect on breast tissue, including by tamoxifen administration [19] , reduces breast cancer risk in BRCA1 mutation carriers.
In summary, bilateral prophylactic mastectomy significantly reduces the risk of breast cancer in BRCA1/2 mutation carriers. Yet despite conclusive evidence that bilateral prophylactic mastectomy reduces breast cancer risk in women with BRCA1/2 mutations by approximately 90%, the decision to undergo bilateral prophylactic mastectomy remains complex. For those women who choose bilateral prophylactic mastectomy, this study provides definitive evidence that they have chosen an effective prevention strategy.
